Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2b Randomized, Double-Masked, Sham-Controlled, Study to Evaluate the Efficacy and Safety of Intravitreal Injection of MCO-010 Optogenetic Therapy in Adults With Retinitis Pigmentosa [RESTORE]

Next Previous
X
Search
Trial Profile

A Phase 2b Randomized, Double-Masked, Sham-Controlled, Study to Evaluate the Efficacy and Safety of Intravitreal Injection of MCO-010 Optogenetic Therapy in Adults With Retinitis Pigmentosa [RESTORE]

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 11 Jul 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Sonpiretigene isteparvovec (Primary)
  • Indications Retinitis pigmentosa
  • Focus Therapeutic Use
  • Acronyms RESTORE
  • Sponsors Nanoscope Therapeutics

    • Most Recent Events

    • 10 Jul 2024 Results published in a Nanoscope Therapeutics Media Release
    • 10 Jul 2024 According to a Nanoscope Therapeutics Media Release, first time 100-week topline results from this trial to be presented in a presentation by Dr. Michael Singer, Clinical Professor of Ophthalmology at the University of Texas Health Science Center, at the 2024 ASRS Annual Scientific Meeting taking place from July 17-July 20, 2024 at the Stockholmsmassan Convention Center in Stockholm, Sweden.
    • 07 May 2024 According to a Nanoscope Therapeutics Media Release, data from this study will be presented at 2024 American Society of Gene + Cell Therapy (ASGCT) Annual Meeting and Retina World Congress being held in Baltimore, Maryland and Fort Lauderdale, Florida,on May 8 and 10 respectively.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top